Analytical Data
-
Gene name
CXCL7
- Application
-
Alternative Names
CXCL7；CTAP3；CXCL7；SCYB7；Platelet basic Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P02775
-
Expression Region
35-128aa
-
AA Sequence
MSSTKGQTKR NLAKGKEESL DSDLYAELRC MCIKTTSGIH PKNIQSLEVI GKGTHCNQVE VIATLKDGRK ICLDPDAPRI KKIVQKKLAG DESAD
-
Molecular Weight
10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL7, also known as platelet factor 4 (PF4), is a chemokine predominantly secreted by activated platelets and plays a significant role in various physiological and pathological processes. Its involvement in inflammation, immune response, and tissue repair makes it a molecule of interest in both basic and clinical research. CXCL7 acts by binding to receptors on the surface of various cell types, influencing cellular migration, activation, and even angiogenesis. Dysregulation of CXCL7 expression has been implicated in several diseases, including atherosclerosis, cancer, and inflammatory disorders. Understanding the functional properties of CXCL7 through recombinant protein studies allows for the exploration of its mechanisms of action and potential therapeutic applications. Additionally, the recombinant CXCL7 protein can be used as a valuable tool for studying its interactions with specific receptors and other signaling pathways. Researchers have focused on developing recombinant CXCL7 to analyze its structural characteristics and biological activities, which can lead to the identification of new drug targets and the development of novel therapeutic strategies. The growing interest in CXCL7 underscores its importance in health and disease, highlighting the necessity for further investigation into its functional roles and potential as a biomarker or therapeutic candidate.
